Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-08-31

Clinical Trial Update: ALF-ONE : ALFuzosin ONcE Daily [Phase 4]

View source ↗

Summary

Phase 4 trial of Alfuzosin taken once daily for benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alfuzosin (ALF-ONE) (alfuzosin)

Snippet

Sponsor: Sanofi | Conditions: Prostatic Hyperplasia | Phase 4 | Status: COMPLETED